ACTRN12611000603910尚未招募4 期
Does scopolamine improve selective attention and cognition more than placebo in healthy male volunteers?
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- Male
入选标准
- •Healthy volunteers
- •Aged 18-40 years
排除标准
- •Current psychiatric or neurological diagnosis
- •Current use of psychotropic medication
- •Current use of cholinergic or anticholinergic medication
- •Medical condition in which scopolamine is contraindicated
研究者
相似试验
已完成
1 期
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy AdultsAlzheimer's DiseaseMemory ImpairmentNCT02051335AstraZeneca27
已完成
1 期
Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)DementiaNCT01181310Merck Sharp & Dohme LLC31
已完成
1 期
A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of CognitionCognitionNCT01044342AstraZeneca20
已完成
1 期
Scopolamine Challenge StudyHealthyNCT01213355Pfizer38
招募中
早期 1 期
Pharmacological Modulation of Brain Oscillations in Memory ProcessingSeizuresCognitive Impairment, MildMemory DisordersMemory LossEpilepsyNCT05594017University of Texas Southwestern Medical Center60